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Background/Aims: This study examined associations of visit-to-visit variability of glycemic control with annual
decline in estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes attending an outpatient clinic.
Methods: Intrapersonal mean and coefficient of variation (CV) of 8-12 measurements of HbA1c and those of 4-6
measurements of fasting and post-breakfast plasma glucose (FPG and PPG, respectively) during the first 12 months
after enrollment were calculated in a cohort of 168 patients with type 2 diabetes. Annual changes in eGFR were
computed using 52 (median) creatinine measurements obtained over a median follow-up of 6.0 years. Multivariate
linear regressions assessed the independent correlates of changes in eGFR.
Results: CV-HbA1c (standardized β、-0.257、p = 0.004) were significantly and log urine albumin/creatinine ratio
(standardized β、-0.155、p = 0.085) and smoking (standardized β、-0.186、p = 0.062) tended to be associated with
annual eGFR decline independently of mean HbA1c, age, sex, BMI, waist circumference, diabetes duration and
therapy, means and CVs of FPG, PPG and systolic blood pressure, baseline eGFR, and uses of anti-hypertensive and
lipid-lowering medications. Association between HbA1c variability and renal function decline was stronger in patients
with albumin/creatinine ratio ≧ 30 mg/g than in those with normoalbuminuria (r = -0.400, p = 0.003 and r = -0.169,
p = 0.07, respectively).
Conclusions: Consistency of glycemic control is important to preserve kidney function in type 2 diabetic patients, in
particular, in those with nephropathy.
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Diabetes is an important cause of mortality and morbidity
worldwide, through both direct clinical sequelae and
increased mortality from cardiovascular and kidney dis-
eases [1]. Long-term glycemic control, as expressed by
hemoglobin (Hb) A1c levels, is the main risk factor for the
development of microvascular complications including dia-
betic kidney disease [2, 3]. Among patients with diabetes* Correspondence: kazumi@mukogawa-u.ac.jp
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progression of microvascular complications such as ne-
phropathy and retinopathy [4]. In addition to high BP and
hyperglycemia, dyslipidemia has an important role in the
progression of kidney disease in patients with diabetes [5].
There is emerging interest to examine the influence of
glycemic and BP variance in diabetic vascular complica-
tions [6, 7]. Recently, variation of HbA1c, a reflection of
long-term glycemic fluctuation, was found to increase the
risk of renal and cardiovascular complications [8–17].
In all studies on renal complications (8–10, 12–17), re-
searchers focused on the relation between HbA1c vari-
ability and development and/or progression of diabeticrticle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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ability and changes in kidney function has hardly been
investigated. We, therefore, asked the question whether
HbA1c variability might directly associated with annual
decline in estimated glomerular filtration rate (eGFR)
in patients with type 2 diabetes attending a long-term
follow-up in a single outpatient clinic.
Methods
The setting for this observational study was an outpatient
diabetes clinic in a private hospital in Japan. Study proto-
col was consistent with the Japanese Government’s Ethical
Guidelines Regarding Epidemiological Studies in ac-
cordance with the Declaration of Helsinki. We examinedTable 1 Anthropometric, clinical and biochemical features of 168 pa
annual changes in estimated glomerular filtration rate and coefficien
Mean ± SD or n, %
Male sex (n, %) 90 ,
Smokers (n, %) 58 ,
Age (years) 62.3 ±
BMI (kg/m2) 24.2 ±
Waist circumference (cm) 86.9 ±
Duration of diabetes (years) 9.9 ±
Treatment of
diabetes; diet/OHA/insulin (%) 31/51/18
hypertension; CCB/RASi/diuretics (%) 34/41/5
HbA1c (%) 7.0 ±
Fasting PG (mg/dL) 125 ±
Post-breakfast PG (mg/dL) 154 ±
CV-HbA1c (%) 7.0 ±
CV-Fasting PG (%) 14.1 ±
CV-Post-breakfast PG (%) 21.9 ±
Total cholesterol (mg/dL) 188 ±
LDL cholesterol (mg/dL) 111 ±
HDL cholesterol (mg/dL) 56 ±
Fasting TG (mg/dL) 115 ±
Post-breakfast TG (mg/dL) 145 ±
Serum creatinine (mg/dL) 0.75 ±
eGFR (mL/min/1.73m2) 76 ±
⊿eGFR (mL/min/1.73m2/year) −1.05 ±
Uric acid (mg/dL) 5.2 ±
Systolic BP (mmHg) 128 ±
CV-Systolic BP (%) 8 ±
Diastolic BP (mmHg) 72 ±
Urinary ACR (mg/g) 84 ±
log ACR 1.30 ±
OHA oral hypoglycemic agents, CCB calcium channel blockers, RASi renin-angiote
estimated glomerular filtration rate, ⊿eGFR; annual changes in eGFR, BP blood pa cohort of 168 patients with type 2 diabetes who had
been regularly attending the clinic in 2004 and 2005. They
were enrolled in the study at the first visit in 2005 and had
at least 8 monthly visits with blood samplings during the
first 12 months after enrollment. Of 168 patients, 153 pa-
tients (91 %) had 12 monthly visits with blood samplings.
In the 153 patients, blood was withdrawn on 2 occasions;
at 2 h after breakfast taken at home and after an overnight
fasting. This was done every other month. In the
remaining 15 patients, blood was obtained after an over-
night fasting. The main clinical features of these subjects
at baseline are reported in Table 1.
After the first visit in 2005 they were followed up in
the subsequent at least 24 months through Decembertients with type 2 diabetes and correlation coefficients of
ts of variation of HbA1c
⊿eGFR CV-HbA1c
54 −0.013 −0.17 *







0.8 −0.050 0.343 ***
22 −0.012 0.299 ***
49 0.047 0.229 **
6.4 −0.187 * 1
9.3 −0.127 0.473 ***
11.0 −0.152 0.190 *
21 0.048 0.025
22 0.0004 0.096
15 0.128 −0.202 **
51 −0.161 * 0.187 *
64 −0.164 * 0.235 **
0.2 −0.042 0.084
16 −0.111 0.165 *





322 −0.208 ** 0.067
0.6 −0.243 ** 0.072
nsin system inhibitors, PG; plasma glucose, CV; coefficient of variation, eGFR;
ressure, ACR albumin/creatinine ratio, *; p < 0.05,**; p < 0.01,***; p < 0.001
Fig. 1 The scatter plot between annual changes in estimated
glomerular filtration rate (⊿eGFR) and coefficient of variations (CV)
of HbA1c
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up of 6.0 years (interquartile range; 4.1–6.5 years). Pa-
tients with hepatitis B surface antigen or antibodies
against hepatitis C virus were excluded. Those who had
aspartate aminotransferase and alanine aminotransferase
of 100 U/L or greater, serum creatinine≧2.0 mg/dL were
excluded as well. Information on smoking habits was
collected through face-to-face interviews by TK. Smoking
status was classified into one of three categories: current
smokers, ex-smokers, and never smokers. Smokers in
statistical analysis included current smokers (n = 52)
and ex-smokers with the Brinkman index of 400 and
higher (n = 5).
For each subject on each monthly visit, waist circum-
ference, weight and BP were measured by registered
nurses. BP using a sphygmomanometer after patients sat
and rested for at least 5 min. Plasma glucose (PG), serum
lipids and lipoproteins, creatinine, hepatic enzymes, uric
acid and other blood tests were measured by standard
methods using an autoanalyzer. HbA1C values were deter-
mined by high performance liquid chromatography and
inter-assay CVs were between 2.0 and 3.0 %. LDL chol-
esterol was calculated using Friedewald’s formula in sam-
ples taken after an overnight fasting. Complete blood
cell count was analyzed using an automated blood cell
counter.
Urinary albumin was measured once during the first
3–4 months after enrollment in random urine samples
using a turbidimetric immunoassay and expressed as
albumin/creatinine ratio (ACR). Serum and urinary
creatinine were measured enzymatically and estimated
glomerular filtration rate (eGFR) was determined using
the equation recommended by the Japanese Society for
Nephrology [18].
Intrapersonal mean and coefficient of variation (CV) of
HbA1c, fasting and post-breakfast plasma glucose (FPG
and PPG, respectively) and serum triglycerides (FTG and
PTG, respectively) taken during the first 12 months after
enrollment were calculated in 168 patients with type 2
diabetes; 153 patients (91 %) had 12 measurements of
HbA1c, systolic BP and 6 measurements of FPG, PPG,
FTG and PTG, respectively. Linear regression was used to
estimate changes in eGFR using a median of 52 creatinine
measurements (interquartile range; 31-60) over 6.0 years
of follow-up in each patient. Baseline means of serum cre-
atinine and eGFR in Table 1 were means of 2–4 measure-
ments during the first 3–4 months after enrollment.
Data were presented as mean ± SD unless otherwise
stated. Differences between 2 groups were analyzed by t
test and frequencies of conditions by Chi-square tests.
Differences among 3 groups were analyzed using analysis
of variance. Correlations of annual eGFR decline and
CV-HbA1c were evaluated by Pearson correlation ana-
lysis. Stepwise multiple linear regression analyses wereperformed to further identify the most significant variables
contributing to annual eGFR decline and CV-HbA1c.
Potential confounders were forced into the model and
standardized β coefficients were calculated. The explana-
tory power of the model was expressed as adjusted R2
values. A two-tailed P < 0.05 was considered statistically
significant. All calculations were performed with SPSS
system 15.0 (SPSS Inc., Chicago, IL).Results
Table 1 shows means of the intrapersonal mean values
during the first 12 months after enrollment, except for
age, duration of diabetes, serum creatinine, eGFR,⊿eGFR
and ACR. Means of age and duration of diabetes were
those on enrollment of patients in the study. Baseline
means of serum creatinine and eGFR in Table 1 were
means of 2–4 measurements during the first 3–4 months
after enrollment. ACR was measured once during the first
3–4 months after enrollment.
Patients had relatively good glycemic, lipid and BP
control with a mean HbA1c of 7.0 %. CVs of HbA1c,
FPG and PPG were 7.0 %, 14.1 % and 21.9 % respectively
(Table 1). Baseline eGFR averaged 76 ± 16 ml/min/1.73m2
and eGFR change was linear and averaged -1.05 ± 3.39 ml/
min/1.73m2 per year. Among 168 patients, 27 (16.0 %)
had eGFR < 60 ml/min/1.73m2 and 53(31.5 %) had albu-
minuria (microalbuminuria 47, macroalbuminuria 6).
Changes in eGFR were inversely associated with CV-
HbA1c (Fig. 1)、FTG、PTG、log ACR and smokers
(Table 1). However, eGFR changes did not show signifi-
cant associations with age, sex, duration of diabetes,
baseline eGFR, treatment for diabetes, mean HbA1c and
mean and CV of FPG, PPG and SBP.
Multiple linear regression analysis (Table 2) revealed
that CV-HbA1c (standardized β、-0.257、p = 0.004) were
associated with and log ACR (standardized β、-0.155、p =
Table 2 Multiple linear regression analysis for coefficient
variation of HbA1c as a dependent variable




waist circumference -.130 .316
duration of diabetes -.047 .622
treatment for diabetes -.121 .231
uses of anti-hypertensive medications .002 .980
uses of lipid-lowering medications .055 .537
smoking -.186 .062
Fasting PG .084 .488
Post-breakfast PG .106 .376
HbA1c .027 .812
CV-HbA1c -.257 .004
Fasting TG -.002 .989
Post-breakfast TG -.072 .665
log ACR -.155 .085
eGFR -.074 .450
Abbreviations are the same as in Table
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tended to be associated with annual eGFR decline inde-
pendently of age, sex, BMI, waist circumference, duration
of and treatment for diabetes, means and CVs of FPG and
PPG, mean HbA1c, baseline eGFR, FTG、PTG, and uses
of anti-hypertensive and lipid-lowering medications.
Patients were divided into 3 groups according to ter-
tiles of CV-HbA1c (Table 3). As CV-HbA1c increased,
the percentage of smokers, mean HbA1c, means and
CVs of FPG and PPG, and TG increased whereas
HDL cholesterol decreased. Diabetic patients in the
highest as compared to the lowest and median tertiles
of CV-HbA1c had faster annual decline in eGFR. Other
parameters including baseline eGFR were not different
among 3 groups.
Association between HbA1c variability and renal function
decline was significant in 53 patients with nephropathy
(ACR≧30 mg/g) but did not reach statistical significance in
115 patients without nephropathy (r = -0.400, p = 0.003
and r = -0.169, p = 0.07, respectively). Compared with pa-
tients with normoalbuminuria, annual eGFR declines
were significantly faster in patients with microalbuminuria
(ACR≧30 mg/g) after controlling for confounders de-
scribed above (-2.0 ± 0.4 (SE) vs. -0.6 ± 0.3 ml/min/1.73m2
per year, p = 0.01).
Discussion
Variations of HbA1c, a reflection of long-term glycemic
fluctuation, were found to increase the risk of chronickidney disease defines as estimated GFR (eGFR) <60 ml/
min/1.73 m2 in some studies in patients with type 2 dia-
betes [14–16]. However, we are not aware of previous
studies to determine whether HbA1c variability might
directly associated with annual decline rate in eGFR in
patients with type 2 as well as type 1 diabetes. The
present study is the first to demonstrate a direct associ-
ation between CV of HbA1c and annual eGFR decline in
patients with diabetes independently of mean HbA1c
and known predictors of GFR decline [19]. Further, asso-
ciation between HbA1c variability and renal function
decline was stronger in patients with nephropathy
(ACR≧30 mg/g) than in those with normoalbuminuria.
By comparison to short-term glucose variability, it has
proven far less difficult to show an association between
HbA1c variability and microvascular complication risk
[20]. It has been shown that HbA1c variability predicted
the development of chronic kidney disease in patients
with type 2 diabetes [14, 16]. Further, Penno et al [15]
have demonstrated that among 8260 patients with type
2 diabetes SD-HbA1c was associated with albuminuric
chronic kidney disease independently of mean HbA1c and
other known predictors of diabetic nephropathy, whereas
mean HbA1c was not. These findings may be in line with
our observation that albuminuria and CV-HbA1c were
directly associated eGFR decline independently of mean
HbA1c and other known predictors of GFR decline. How-
ever, among 4399 patients with type 2 diabetes in the in-
tensive group of the ADVANCE trial [17], the association
between SD of HbA1c and microvascular events did not
reach statistical significance (p = 0.06 for trend) although
there were significant linear associations of SD of HbA1c
with combined macro—and microvascular events, major
macrovascular events and all-cause mortality.
Although glycemic variability has been inconsistently
associated with the risk of vascular complications in
diabetes [21], several reasons may be involved in the as-
sociation between visit-to-visit HbA1c variability and
outcomes as suggested by Kilpatrick et al [20, 21]. They
include ‘metabolic memory’ phenomenon [22]. They
may be related to the fact that microvascular complica-
tion risk rises exponentially, rather than linearly, as
HbA1c rises. They also may be related to the observa-
tion that acute improvement in HbA1c can lead to a
short-term “early” worsening in retinopathy before sub-
sequently resulting in a net long-term improvement. It
is also possible that patient with HbA1c variability are
those in whom the rest of their diabetes management is
suboptimal.
Type 2 diabetic patients in the present study had an-
nual eGFR decline which was even slower as compared
with non-diabetic Japanese patients with early-stage chronic
kidney disease (eGFR > 60 ml/min/1.73m2) [23] (-1.05
vs. -1.64 ml/min/1.73m2 per year). Further, annual eGFR
Table 3 Anthropometric, clinical and biochemical features of patients with type 2 diabetes according to tertiles of CV-HbA1c
CV-HbA1c tertiles
Low Median High
(1.17-3.64) (3.64-6.50) (6.50-28.65) p values
Smokers (n, %) 10 , 18.2 22 , 39.3 25 , 44.6 0.008
Age (years) 63.6 ± 9.6 62.3 ± 9.4 61.2 ± 11.3 0.453
BMI (kg/m2) 24.0 ± 3.9 24.1 ± 3.0 24.6 ± 4.0 0.638
Waist circumference (cm) 87.2 ± 9.4 86.6 ± 8.7 87.0 ± 11.5 0.959
Duration of diabetes (years) 9.2 ± 7.7 10.6 ± 6.7 9.8 ± 7.5 0.622
Treatment of
diabetes; diet/OHA/insulin (%) 43/50/7 32/45/23 20/ 57/ 23 0.026
hypertension; CCB/RASi/diuretics (%) 36/39/5 30/41/4 38/ 45/ 5 0.424
HbA1c (%) 6.6 ± 0.6 7.1 ± 0.7 7.4 ± 1.0 <0.001
Fasting PG (mg/dL) 114 ± 14 129 ± 24 133 ± 23 <0.001
Post-breakfast PG (mg/dL) 135 ± 40 160 ± 49 169 ± 51 0.001
CV-HbA1c (%) 2.5 ± 0.7 4.9 ± 0.9 13.6 ± 7.3 <0.001
CV-Fasting PG (%) 8.8 ± 3.9 14.1 ± 9.7 19.5 ± 9.6 <0.001
CV-Post-breakfast PG (%) 18 ± 10 23 ± 11 25 ± 11 0.007
Total cholesterol (mg/dL) 188 ± 19 189 ± 18 187 ± 25 0.890
LDL cholesterol (mg/dL) 108 ± 17 111 ± 23 114 ± 25 0.288
HDL cholesterol (mg/dL) 60 ± 15 57 ± 17 50 ± 12 0.001
Fasting TG (mg/dL) 102 ± 43 112 ± 49 130 ± 58 0.017
Post-breakfast TG (mg/dL) 131 ± 59 144 ± 65 137 ± 65 0.047
Serum creatinine (mg/dL) 0.73 ± 0.15 0.73 ± 0.15 0.80 ± 0.25 0.072
eGFR (mL/min/1.73m2) 74 ± 12 76 ± 15 77 ± 21 0.641
⊿eGFR (mL/min/1.73m2/year) −0.69 ± 2.77 −0.63 ± 2.29 −2.19 ± 3.68 0.008
Uric acid (mg/dL) 5.3 ± 1.5 5.0 ± 1.4 5.2 ± 1.1 0.495
Systolic BP (mmHg) 128 ± 12 129 ± 11 128 ± 13 0.905
CV-Systolic BP (%) 8.2 ± 2.3 7.6 ± 2.1 8.3 ± 2.2 0.254
Diastolic BP (mmHg) 72 ± 6 72 ± 7 72 ± 7 0.787
Urinary ACR (mg/g) 21 ± 24 69 ± 152 162 ± 532 0.066
log ACR 1.1 ± 0.5 1.4 ± 0.6 1.4 ± 0.7 0.012
Mean ± SD or n, %. Abbreviations are the same as in Table 1
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found in a previous study of Japanese type 2 diabetic pa-
tients without clinical albuminuria (-2.94 ml/min/1.73m2
per year) [24] despite comparable baseline eGFR (76 and
75 ml/min/1.73m2). These findings may be due in part to
the fact that our patients had better glycemic (mean
HbA1c; 7.0 vs. 8.4 %) and BP (128/72 vs. 135/81 mmHg)
control. Slower eGFR decline associated with better dia-
betic control in our patients may be related to failure to
detect association between mean HbA1c and annual eGFR
decline in the present study.
In the present study, patients with microalbuminuria
had faster decline of eGFR than those with normoalbu-
minuria. This finding may be in line with previous stud-
ies that urinary albumin, even in the microalbuminuricrange, is a predictor of renal function impairment in the
general population [25], type 2 diabetic patients with
preserved kidney function [26, 27] and in CKD patients
(GFR < 50 ml/min) [28]. In the last-cited longitudinal
observational study [28], Lorenzo et al. compared the
rate of renal decline in diabetic and non-diabetic CKD
patients with comparable levels of albuminuria. They
found that urinary ACR was a robust predictor of poor
outcome. In addition, the mean slope of renal decline
was similar in diabetic and non-diabetic patients when
controlling for albuminuria.
The strength of the current study is that we used a 1-
year period when mean HbA1c and HbA1c variability
were calculated from 12 measurements in 91 % partici-
pants. In addition, we measured serum creatinine and
Takenouchi et al. Journal of Diabetes & Metabolic Disorders  (2015) 14:69 Page 6 of 7hence eGFR during follow-up period much more frequently
than in previous studies [14–16]. This could contribute to
the reliability of changes in kidney function. Such a testing
frequency is routine in clinical settings in Japan. However,
frequent measures of HbA1c may artificially inflate preci-
sion and decrease standard deviation, which may impact
the results. Finally, BP control and variability and postpran-
dial TG also have been taken into accounted. Major limita-
tions are that study participants were small in number and
from a single clinic in Japan. However, the characteristics of
our study participants are similar to those reported in a
previous large-scale study in Japan [29].Conclusions
The current study has shown direct association between
HbA1c variability and kidney function decline in type 2
diabetic patients and demonstrated stronger association
in patients with microalbuminuria than in patients with
normoalbuminuria. These findings suggest that more at-
tention should be paid by clinicians in diabetes control,
avoiding excessive oscillations in blood glucose levels in
type 2 diabetic patients in general and in those with
microalbuminuria in particular. Further studies are needed
to confirm the association in other ethnic groups with
more patients.
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